Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Stockholm, Sweden.
PLoS One. 2018 May 15;13(5):e0197183. doi: 10.1371/journal.pone.0197183. eCollection 2018.
Proteins belonging to the linear ubiquitin assembly complex (LUBAC) are believed to be important in tumorigenesis. LUBAC has been demonstrated to be composed of RBCK1, RNF31 and SHARPIN. The aim of this study was to explore all members of the LUBAC complex as novel biomarkers in breast cancer. We have already reported that RNF31 mRNA levels are higher in breast cancer samples compared to adjacent non-tumor tissue. In this study we extend these findings by demonstrating that the mRNA levels of RBCK1 and SHARPIN are also higher in tumors compared to adjacent non-tumor tissue in the same cross sectional study of samples (p < 0.001). In addition, up-regulated mRNA expression of all three members of the LUBAC complex displayed high predictive value in distinguishing tumor tissues from adjacent non-tumor tissue as determined by ROC curve analysis. Furthermore, we investigated whether there is an association between the mRNA and protein expression levels of RBCK1, RNF31 and SHARPIN and clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) status and found that RNF31 protein is significantly higher in ERalpha-negative tumors than ERalpha-positive tumors (p = 0.034). Collectively, our findings indicate that up-regulated mRNA expression of RNF31, RBCK1 and SHARPIN could potentially be diagnostic biomarkers of breast cancer and RNF31 might be a drug target for ERalpha-negative breast cancers.
属于线性泛素连接酶复合物(LUBAC)的蛋白质被认为在肿瘤发生中很重要。已经证明 LUBAC 由 RBCK1、RNF31 和 SHARPIN 组成。本研究旨在探索 LUBAC 复合物的所有成员作为乳腺癌的新型生物标志物。我们已经报道过,与相邻非肿瘤组织相比,乳腺癌样本中的 RNF31 mRNA 水平更高。在这项研究中,我们通过证明在相同的样本横断面研究中,与相邻非肿瘤组织相比,RBCK1 和 SHARPIN 的 mRNA 水平在肿瘤中也更高,扩展了这些发现(p < 0.001)。此外,通过 ROC 曲线分析,LUBAC 复合物所有三个成员的上调 mRNA 表达在区分肿瘤组织与相邻非肿瘤组织方面具有很高的预测价值。此外,我们还研究了 RBCK1、RNF31 和 SHARPIN 的 mRNA 和蛋白表达水平与包括雌激素受体(ER)、孕激素受体(PR)和人类表皮生长因子受体(HER2)状态在内的临床病理参数之间是否存在关联,并发现 RNF31 蛋白在 ERalpha-阴性肿瘤中的表达明显高于 ERalpha-阳性肿瘤(p = 0.034)。综上所述,我们的研究结果表明,RNF31、RBCK1 和 SHARPIN 的上调 mRNA 表达可能是乳腺癌的潜在诊断生物标志物,而 RNF31 可能是 ERalpha-阴性乳腺癌的药物靶点。